Timothy J. Hobday - Concepedia

Author

Timothy J. Hobday

Also Known As

Ebrahim Delpassand, Guo, Hao, Hobday, T.J., Hobday, Timothy J., Ingrid A. Mayer, Mayer, Erica L., Pingpank, James, Robert Hobbs, T Hobday, T J Hobday

250

Publications

12.7K

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic in Arizona Mayo Clinic Mayo Clinic in Florida The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute

About

Timothy J. Hobday is an author at Mayo Clinic in Arizona specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	35	2.1K
2	Health Sciences	11	11	704
3	Engineering	1	1	16
4	Public Health	1	1	20
5	Biostatistics	1	1	16

Timothy J. Hobday

Publications

11.7K

Citations

H-Index

Page 1

	Year	Citations
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, New England Journal of Medicine	2017	3K
Everolimus for Advanced Pancreatic Neuroendocrine Tumors James C. Yao, Manisha H. Shah, Tetsuhide Ito, New England Journal of Medicine	2011	2.8K
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Journal of Clinical Oncology Octreotide LarSurgical OncologyPancreatic CancerPhase Ii TrialGastrointestinal Oncology	2009	648
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer Lisa A. Carey, Hope S. Rugo, P. Kelly Marcom, Journal of Clinical Oncology	2012	489
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial Jonathan Strosberg, Edward M. Wolin, Beth Chasen, Journal of Clinical Oncology	2018	375
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer X. Cynthia, Feng Gao, Jingqin Luo, Clinical Cancer Research	2017	359
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting Matthew H. Kulke, Lillian L. Siu, Joel E. Tepper, Journal of Clinical Oncology Somatostatin AnalogPathologyNet Task ForceTumor BiologyOncology	2011	304
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study James C. Yao, Marianne Pavel, Catherine Lombard‐Bohas, Journal of Clinical Oncology	2016	262
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221) Christine B. Ambrosone, Gary Zirpoli, Alan D. Hutson, Journal of Clinical Oncology	2019	225
Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer Pamela J. Goodwin, Bingshu E. Chen, Karen A. Gelmon, JAMA	2022	207

Page 1